News

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...
There's one main way to treat inflammatory bowel disease (IBD): Control inflammation by whipping the immune system into shape ...
Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.
Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sanders, 56, revealed he suffered a heart attack on Father’s Day in 2024 —an event he also discusses in the new Amgen/A&E ...
A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, ...
Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.
For the second time in three years, Bob Bradway raked in the most of any executive of a public company based on the Central Coast in 2024, generating a total compensation package worth $24.4 million, ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The idea for Amgen’s first foray into documentary film started with two numbers, according to Nerissa Gomes, general manager ...